Cargando…

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study

BACKGROUND: We wanted to evaluate if health care for multiple myeloma (MM) patients is equal in different regions of Sweden. AIM: To study differences in survival for MM depending on health care region and early use of modern treatment. METHODS AND RESULTS: Data from the Swedish Myeloma Register fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wålinder, Göran, Genell, Anna, Juliusson, Gunnar, Svensson, Ronald, Santamaria, Antonio Izarra, Crafoord, Jacob, Carlson, Kristina, Knut‐Bojanowska, Dorota, Veskovski, Ljupco, Lauri, Birgitta, Lund, Johan, Turesson, Ingemar, Hansson, Markus, Blimark, Cecilie Hveding, Nahi, Hareth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675390/ https://www.ncbi.nlm.nih.gov/pubmed/35243814 http://dx.doi.org/10.1002/cnr2.1614

Ejemplares similares

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
por: Blimark, Cecilie Hveding, et al.
Publicado: (2018)

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
por: Moore, Kari Lenita Falck, et al.
Publicado: (2022)

Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
por: Ali, Mina, et al.
Publicado: (2019)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients
por: Lemonakis, Konstantinos, et al.
Publicado: (2022)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends
por: Vélez, Ramón, et al.
Publicado: (2016)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
por: Ali, Mina, et al.
Publicado: (2018)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
por: Swaminathan, Bhairavi, et al.
Publicado: (2015)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients
por: Tahiru, Widad, et al.
Publicado: (2022)

Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma
por: Abildgaard, Niels, et al.
Publicado: (2023)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023)

Fractures and survival in multiple myeloma: results from a population-based study
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2020)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
por: Hemminki, Kari, et al.
Publicado: (2021)

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Silvennoinen, Raija, et al.
Publicado: (2023)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
por: Westhrin, Marita, et al.
Publicado: (2018)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples
por: Späth, Florentin, et al.
Publicado: (2019)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study
por: Lindqvist, Ebba K., et al.
Publicado: (2016)

Germline variants at SOHLH2 influence multiple myeloma risk
por: Duran-Lozano, Laura, et al.
Publicado: (2021)

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2016)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
por: Iida, Shinsuke, et al.
Publicado: (2021)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

Cancer incidence in northern Sweden before and after the Chernobyl nuclear power plant accident
por: Alinaghizadeh, Hassan, et al.
Publicado: (2014)

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
por: Groen, K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v8fsr8sesqh5vb8ou6teu3bu77